[FG] Kappos Ludwig

Lorscheider, Johannes et al. (2024) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network’, Journal of Neurology, Neurosurgery & Psychiatry, pp. jnnp–2024–334700. Available at: https://doi.org/10.1136/jnnp-2024-334700.

Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.03.22.24304720.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102. Available at: https://doi.org/10.1212/wnl.0000000000207768.

Derfuss, T. et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.

Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology, 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.

Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271, pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.

Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology [Preprint]. Available at: https://doi.org/10.1002/ana.26886.

Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology, 81, pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.

Wali, Nabila et al. (2024) ‘Endovascular treatment in patients with acute ischemic stroke presenting beyond 6 h after symptom onset: An international multicenter cohort study of the EVA-TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241277437.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), p. 1317. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis’, JAMA Neurology, 80(11), p. 1232. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.

Hauser S.L. et al. (2023) ‘The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment’, Neurology and Therapy, 12(5), pp. 1491–1515. Available at: https://doi.org/10.1007/s40120-023-00518-0.

Seystahl K et al. (2023) ‘IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors.’, Neurology, 101(12), pp. e1241–e1255. Available at: https://doi.org/10.1212/wnl.0000000000207624.

Woelfle T et al. (2023) ‘Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.’, Journal of medical Internet research, 25, p. e44428. Available at: https://doi.org/10.2196/44428.

Baumgartner P et al. (2023) ‘Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study.’, European stroke journal, p. 23969873231185895. Available at: https://doi.org/10.1177/23969873231185895.

Diouf I et al. (2023) ‘Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.’, Journal of neurology, neurosurgery, and psychiatry [Preprint]. Available at: https://doi.org/10.1136/jnnp-2023-331499.

Pless S et al. (2023) ‘Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.’, Journal of neurology, 270(7), pp. 3451–3463. Available at: https://doi.org/10.1007/s00415-023-11671-9.

Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.

Pfeuffer S. et al. (2023) ‘Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab’, Neurology(R) neuroimmunology & neuroinflammation, 10(3). Available at: https://doi.org/10.1212/nxi.0000000000200104.

Agosti, Reto et al. (2023) ‘Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study’, Pain and Therapy, 12(2), pp. 575–591. Available at: https://doi.org/10.1007/s40122-023-00484-3.

Cagol A. et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.’, Journal of neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.

Diouf I. et al. (2023) ‘Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis’, European Journal of Neurology, 30(4), pp. 1014–1024. Available at: https://doi.org/10.1111/ene.15706.

Vrenken H. et al. (2023) ‘Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a’, Journal of Neurology, 270(4), pp. 2271–2282. Available at: https://doi.org/10.1007/s00415-022-11554-5.

Hauser S.L. et al. (2023) ‘Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 10(2). Available at: https://doi.org/10.1212/nxi.0000000000200094.

Al-Ajlan FS et al. (2023) ‘Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial.’, Stroke, 54(3), pp. 715–721. Available at: https://doi.org/10.1161/strokeaha.121.038475.

Bakker, M.K. et al. (2023) ‘Genetic Risk Score for Intracranial Aneurysms: Prediction of Subarachnoid Hemorrhage and Role in Clinical Heterogeneity’, Stroke, 54(3), pp. 810–818. Available at: https://doi.org/10.1161/strokeaha.122.040715.

Kuhle J et al. (2023) ‘Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial’, Multiple Sclerosis Journal, 29(3), pp. 385–394. Available at: https://doi.org/10.1177/13524585221144742.

Tsagkas C et al. (2023) ‘Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis’, Multiple Sclerosis and Related Disorders, 71, p. 104545. Available at: https://doi.org/10.1016/j.msard.2023.104545.

Marto JP et al. (2023) ‘Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.’, Neurology, 100(7), pp. e739–e750. Available at: https://doi.org/10.1212/wnl.0000000000201537.

Tsagkas C et al. (2023) ‘Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.’, AJNR. American journal of neuroradiology, 44(2), pp. 218–227. Available at: https://doi.org/10.3174/ajnr.a7756.

Ziemssen T. et al. (2023) ‘Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies’, Neurology: Neuroimmunology and NeuroInflammation, 10(1). Available at: https://doi.org/10.1212/nxi.0000000000200064.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80, pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Achtnichts, Lutz et al. (2023) ‘Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: Primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)’, BMJ Neurology Open, 5. Available at: https://doi.org/10.1136/bmjno-2022-000304.

Alexander Salerno et al. (2023) ‘BEST REVASCULARIZATION APPROACH FOR POSTERIOR CIRCULATION STROKES WITH ISOLATED VERTEBRAL ARTERY OCCLUSIONS: RESULTS FROM THE “BRAVO” RETROSPECTIVE STUDY ’, in European Stroke Organisation Conference . Munich, Germany (European Stroke Organisation Conference ).

Alexandros Polymeris et al. (2023) ‘OUTCOMES OF ATRIAL FIBRILLATION KNOWN BEFORE OR DETECTED AFTER ISCHEMIC STROKE: ROLE OF ANTICOAGULATION’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Altersberger, Valerian L. et al. (2023) ‘Intravenous Thrombolysis 4.5–9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration’, Annals of Neurology. 28.04.2023, 94(2), pp. 309–320. Available at: https://doi.org/10.1002/ana.26669.

Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.

Bühler A et al. (2023) ‘Recurrent disability progression endpoints in multiple sclerosis clinical trials.’, Multiple sclerosis (Houndmills, Basingstoke, England), 29(1), pp. 130–139. Available at: https://doi.org/10.1177/13524585221125382.

Callegari, Ilaria et al. (2023) ‘Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150040.

Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.

Chen, Xinjie et al. (2023) ‘Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients’, NeuroImage: Clinical, 37. Available at: https://doi.org/10.1016/j.nicl.2023.103349.

Dittrich, Tolga D et al. (2023) ‘Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications – the PLEURA study’, European Stroke Journal, 8, pp. 549–556. Available at: https://doi.org/10.1177/23969873231151488.

Dittrich, Tolga D et al. (2023) ‘Mechanical thrombectomy for large vessel occlusion between 6 and 24 h: outcome comparison of DEFUSE-3/DAWN eligible versus non-eligible patients’, International Journal of Stroke, 18, pp. 697–703. Available at: https://doi.org/10.1177/17474930221140793.

Dittrich, Tolga D. et al. (2023) ‘Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study’, Stroke, 54, pp. 722–730. Available at: https://doi.org/10.1161/strokeaha.122.039793.

Gentile G. et al. (2023) ‘The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study’, NeuroImage: Clinical, 38. Available at: https://doi.org/10.1016/j.nicl.2023.103397.

Granziera, Cristina, Derfuss, Tobias and Kappos, Ludwig (2023) ‘Time to Change the Current Clinical Classification of Multiple Sclerosis?’, JAMA Neurology, 80, pp. 128–130. Available at: https://doi.org/10.1001/jamaneurol.2022.4156.

Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.

JE Kaufmann et al. (2023) ‘Towards Individual Treatment in Cervical Artery Dissection—An In‑Depth Analysis of the TREAT‑CAD Randomised Trial’, in Annual Meeting of the Swiss Neurological Society and Swiss Society of Neurosurgery. Zurich (Annual Meeting of the Swiss Neurological Society and Swiss Society of Neurosurgery).

Josefin E. Kaufmann et al. (2023) ‘TOWARDS INDIVIDUAL TREATMENT IN CERVICAL ARTERY DISSECTION - AN INDEPTH ANALYSIS OF THE TREAT-CAD RANDOMISED TRIAL’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Kappos L., Barkhof F. and Uitdehaag B. (2023) ‘Otto van Eikema Hommes – 7 February 1932 – 16 August 2022’, Multiple Sclerosis Journal, 29(1), pp. 6–7. Available at: https://doi.org/10.1177/13524585221139153.

K. Seystahl et al. (2023) ‘ INTRAVENOUS THROMBOLYSIS WITH OR WITHOUT ENDOVASCULAR TREATMENT FOR SUSPECTED ISCHEMIC STROKE IN PATIENTS WITH INTRACRANIAL TUMORS’, in 18th Meeting of the European Association of Neuro-Oncology. Rotterdam, Netherlands (18th Meeting of the European Association of Neuro-Oncology).

Lyrer, Flurina et al. (2023) ‘Atrial Fibrillation Detected before or after Stroke: Role of Anticoagulation’, Annals of Neurology, 94, pp. 43–54. Available at: https://doi.org/10.1002/ana.26654.

Meinel, Thomas R. et al. (2023) ‘Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants’, JAMA Neurology, 80, pp. 233–243. Available at: https://doi.org/10.1001/jamaneurol.2022.4782.

Signori A et al. (2023) ‘Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.’, Journal of neurology, neurosurgery, and psychiatry, 94(1), pp. 23–30. Available at: https://doi.org/10.1136/jnnp-2022-329987.

Todea, Alexandra Ramona et al. (2023) ‘A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients’, Journal of Magnetic Resonance Imaging, 58, pp. 864–876. Available at: https://doi.org/10.1002/jmri.28618.

Tolga Dittrich et al. (2023) ‘APICAL PULMONARY LESIONS SUSPECTED OF MALIGNANCY VISIBLE ON NECK CT ANGIOGRAPHY PERFORMED FOR ACUTE STROKE: PREVALENCE, REATMENT AND CLINICAL IMPLICATIONS – THE PLEURA STUDY’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Traenka, Christopher et al. (2023) ‘Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration’, Journal of Stroke, 25, pp. 272–281. Available at: https://doi.org/10.5853/jos.2022.03370.

Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29, pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.

Wenger A.L. et al. (2023) ‘An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis’, Frontiers in Neuroscience, 17. Available at: https://doi.org/10.3389/fnins.2023.1007580.

Woelfle, Tim et al. (2023) ‘Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105104.

Woelfle T et al. (2023) ‘Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.’, Journal of neurology, 270(1), pp. 262–271. Available at: https://doi.org/10.1007/s00415-022-11306-5.

Chang I et al. (2022) ‘Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(14), pp. 2263–2273. Available at: https://doi.org/10.1177/13524585221114997.

Meaton I et al. (2022) ‘Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(14), pp. 2212–2220. Available at: https://doi.org/10.1177/13524585221118677.

Ovchinnikov, Arkady and Findling, Oliver (2022) ‘An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis’, Wiener Medizinische Wochenschrift, 172(15-16), pp. 359–364. Available at: https://doi.org/10.1007/s10354-022-00939-w.

Sztajzel RF et al. (2022) ‘Carotid plaque surface echogenicity predicts cerebrovascular events: An Echographic Multicentric Swiss Study.’, Journal of neuroimaging : official journal of the American Society of Neuroimaging, 32(6), pp. 1142–1152. Available at: https://doi.org/10.1111/jon.13026.

Roos I et al. (2022) ‘Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.’, Neurology, 99(17), pp. e1926–e1944. Available at: https://doi.org/10.1212/wnl.0000000000201029.

Leppert D et al. (2022) ‘Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.’, Neurology, 99(14), p. 631. Available at: https://doi.org/10.1212/wnl.0000000000201277.

Altersberger VL et al. (2022) ‘Thrombolysis in stroke patients with elevated inflammatory markers.’, Journal of neurology, 269(10), pp. 5405–5419. Available at: https://doi.org/10.1007/s00415-022-11173-0.

Cree BA et al. (2022) ‘Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(12), pp. 1944–1962. Available at: https://doi.org/10.1177/13524585221102584.

Kalincik T et al. (2022) ‘Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(11), pp. 1752–1761. Available at: https://doi.org/10.1177/13524585221084577.

Sprenger T et al. (2022) ‘Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(11), pp. 1719–1728. Available at: https://doi.org/10.1177/13524585221089534.

Arnold DL et al. (2022) ‘Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(10), pp. 1526–1540. Available at: https://doi.org/10.1177/13524585221076717.

Cree BA et al. (2022) ‘Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(10), pp. 1591–1605. Available at: https://doi.org/10.1177/13524585221083194.

Gärtner J et al. (2022) ‘Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(10), pp. 1562–1575. Available at: https://doi.org/10.1177/13524585221078825.

Gold R et al. (2022) ‘Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.’, Journal of neurology, 269(9), pp. 5093–5104. Available at: https://doi.org/10.1007/s00415-022-11166-z.

Hauser SL et al. (2022) ‘Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(10), pp. 1576–1590. Available at: https://doi.org/10.1177/13524585221079731.

Lam KH et al. (2022) ‘Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.’, International journal of MS care, 24(5), pp. 230–234. Available at: https://doi.org/10.7224/1537-2073.2021-044.

Rahmanzadeh R et al. (2022) ‘A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.’, Annals of neurology, 92(3), pp. 486–502. Available at: https://doi.org/10.1002/ana.26441.

Granziera C, Woelfle T and Kappos L (2022) ‘Development and implementation of new diagnostic technologies in neurology.’, Nature reviews. Neurology, 18(8), pp. 445–446. Available at: https://doi.org/10.1038/s41582-022-00692-z.

Parmar K et al. (2022) ‘Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.’, Cerebellum (London, England), 21(4), pp. 632–646. Available at: https://doi.org/10.1007/s12311-021-01312-0.

Sharmin S et al. (2022) ‘Confirmed disability progression as a marker of permanent disability in multiple sclerosis.’, European journal of neurology, 29(8), pp. 2321–2334. Available at: https://doi.org/10.1111/ene.15406.

Tur C et al. (2022) ‘The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(9), pp. 1424–1456. Available at: https://doi.org/10.1177/13524585211069068.

Battaglini M et al. (2022) ‘Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.’, European journal of neurology, 29(7), pp. 2024–2035. Available at: https://doi.org/10.1111/ene.15314.

Manuel Escobar J et al. (2022) ‘Body mass index as a predictor of MS activity and progression among participants in BENEFIT.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(8), pp. 1277–1285. Available at: https://doi.org/10.1177/13524585211061861.

Altersberger VL et al. (2022) ‘Effect of admission time on provision of acute stroke treatment at stroke units and stroke centers-An analysis of the Swiss Stroke Registry.’, European stroke journal, 7(2), pp. 117–125. Available at: https://doi.org/10.1177/23969873221094408.

Leppert D et al. (2022) ‘Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.’, Neurology, 98(21), pp. e2120–e2131. Available at: https://doi.org/10.1212/wnl.0000000000200258.

Müller J et al. (2022) ‘Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.’, Neurology(R) neuroimmunology & neuroinflammation, 9(3). Available at: https://doi.org/10.1212/nxi.0000000000001147.

Wagner B et al. (2022) ‘Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia: A Matched Comparison.’, Stroke, 53(5), pp. 1520–1529. Available at: https://doi.org/10.1161/strokeaha.121.034934.

Wendebourg MJ et al. (2022) ‘Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome.’, European journal of neurology, 29(5), pp. 1435–1445. Available at: https://doi.org/10.1111/ene.15261.

Butzkueven H. et al. (2022) ‘Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry’, European Journal of Neurology, 29(4), pp. 1082–1090. Available at: https://doi.org/10.1111/ene.14824.

Giovannoni G. et al. (2022) ‘Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials’, European Journal of Neurology, 29(4), pp. 1238–1242. Available at: https://doi.org/10.1111/ene.14823.

Gold R. et al. (2022) ‘Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results’, Multiple Sclerosis Journal, 28(5), pp. 801–816. Available at: https://doi.org/10.1177/13524585211037909.

Kuhle J et al. (2022) ‘Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.’, Multiple sclerosis (Houndmills, Basingstoke, England), 28(4), pp. 573–582. Available at: https://doi.org/10.1177/13524585211032348.

Malpas CB et al. (2022) ‘Multiple Sclerosis Relapses Following Cessation of Fingolimod.’, Clinical drug investigation, 42(4), pp. 355–364. Available at: https://doi.org/10.1007/s40261-022-01129-7.

Schiavi S et al. (2022) ‘Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography.’, NeuroImage, 249, p. 118922. Available at: https://doi.org/10.1016/j.neuroimage.2022.118922.

Zandl-Lang M et al. (2022) ‘Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome.’, Metabolites, 12(4). Available at: https://doi.org/10.3390/metabo12040291.